Physician profile
Michael Damiano
NPI 1326039413
$1,742.36
in general payments reported to CMS, 2019-2025
21 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $250 · 2021: $418 · 2022: $418 · 2023: $128 · 2024: $91.53 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.05 | 2019-2023 | Skyrizi |
| Astrazeneca Pharmaceuticals LP | $205.53 | 2021-2024 | Fasenra |
| Merck Sharp & Dohme LLC | $125.00 | 2019 | |
| Aimmune Therapeutics, INC. | $124.98 | 2025 | Zenpep |
| Paratek Pharmaceuticals, INC. | $122.90 | 2020 | |
| Ucb, INC. | $112.59 | 2021-2023 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.55 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $97.39 | 2021-2023 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $93.85 | 2022 | |
| Leo Pharma INC. | $86.17 | 2020-2023 | Adbry |
| Janssen Biotech, INC. | $65.10 | 2019-2021 | |
| Sientra, INC. | $59.00 | 2021 | |
| Lilly USA, LLC | $51.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $40.60 | 2021-2022 | |
| Galderma Laboratories, L.P. | $33.50 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.95 | 2022-2023 | Otezla |
| Incyte Corporation | $29.00 | 2022 | |
| Pfizer INC. | $22.06 | 2020 | |
| Sun Pharmaceutical Industries INC. | $20.28 | 2022 | |
| Mayne Pharma Commercial LLC | $20.19 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Damiano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.